Reparixin

N/A

Report date: 2026/02/25 20:02:36
NME

Base Information

Drug NameReparixin
Drug Alias Name瑞帕利星Repertaxinreparixina瑞帕立辛reparixinum +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-X-C motif chemokine receptor 2 antagonistsC-X-C motif chemokine receptor 1 antagonists
TargetsC-X-C motif chemokine receptor 1C-X-C motif chemokine receptor 2
Therapy Area/IndicationsRejection of lung transplantationCoronavirus Disease 2019 (COVID-19)Metastatic breast cancer +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[15] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesDompe Farmaceutici Spa
China Registration ClassN/A

Develop Information

Active CompaniesDompé farmaceutici SPAIcahn School Of Medicine At Mount Sinai
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Primary MyelofibrosisRespiratory Distress Syndrome, Adult
Inactive IndicationsRejection of lung transplantationMetastatic breast cancerFatigue +[9] 

Other Information

ATC CodeN/A
Related LinksKEGG